메뉴 건너뛰기




Volumn 4, Issue 3, 1997, Pages 213-216

Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

EID: 0030760830     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704030-00010     Document Type: Short Survey
Times cited : (5)

References (21)
  • 1
    • 0026688428 scopus 로고
    • Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor-β1 and cancer chemotherapy compounds in myeloid leukemic cells
    • Lotem J, Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor-β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992, 80:1750-1757.
    • (1992) Blood , vol.80 , pp. 1750-1757
    • Lotem, J.1    Sachs, L.2
  • 2
    • 0026533427 scopus 로고
    • GM-CSF and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effects on clonogenic cells from patients with acute myeloid leukemia
    • Hiddemann W, Kiehl M, Zuhlsdorf M, Busemann C, Schleyer E, Wormann B, Buchner T: GM-CSF and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effects on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol 1992, 19:31-37.
    • (1992) Semin Oncol , vol.19 , pp. 31-37
    • Hiddemann, W.1    Kiehl, M.2    Zuhlsdorf, M.3    Busemann, C.4    Schleyer, E.5    Wormann, B.6    Buchner, T.7
  • 3
    • 0027978963 scopus 로고
    • Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia
    • Gandhi V, Du M, Kantarjian HM, Plunkett W: Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia 1994, 8:1463-1468.
    • (1994) Leukemia , vol.8 , pp. 1463-1468
    • Gandhi, V.1    Du, M.2    Kantarjian, H.M.3    Plunkett, W.4
  • 4
    • 0025950205 scopus 로고
    • Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity
    • Koistinen P, Wang C, Curtis JE, McCulloch EA: Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 1991, 5:789-795.
    • (1991) Leukemia , vol.5 , pp. 789-795
    • Koistinen, P.1    Wang, C.2    Curtis, J.E.3    McCulloch, E.A.4
  • 6
    • 0025800331 scopus 로고
    • Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer by granulocyte colony-stimulating factor (R-metG-CSF)
    • Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al.: Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer by granulocyte colony-stimulating factor (R-metG-CSF). N Engl J Med 1991, 325:164-171.
    • (1991) N Engl J Med , vol.325 , pp. 164-171
    • Crawford, J.1    Ozer, H.2    Stoller, R.3    Johnson, D.4    Lyman, G.5    Tabbara, I.6
  • 7
    • 0028891412 scopus 로고
    • Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy
    • De Haan G, Engel C, Dontje B, Loeffler M, Nijhof W: Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy. Cancer Res 1995, 55:324-329. Simultaneous administration of etoposide and G-CSF protected normal mice from the subsequent development of neutropenia.
    • (1995) Cancer Res , vol.55 , pp. 324-329
    • De Haan, G.1    Engel, C.2    Dontje, B.3    Loeffler, M.4    Nijhof, W.5
  • 8
    • 0023945042 scopus 로고
    • Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
    • Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, et al.: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988, 318:1414-1422.
    • (1988) N Engl J Med , vol.318 , pp. 1414-1422
    • Gabrilove, J.L.1    Jakubowski, A.2    Scher, H.3    Sternberg, C.4    Wong, G.5    Grous, J.6    Yagoda, A.7    Fain, K.8    Moore, M.A.9    Clarkson, B.10
  • 10
    • 0026732612 scopus 로고
    • Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy
    • Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM: Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992, 84:1201-1203.
    • (1992) J Natl Cancer Inst , vol.84 , pp. 1201-1203
    • Meropol, N.J.1    Miller, L.L.2    Korn, E.L.3    Braitman, L.E.4    MacDermott, M.L.5    Schuchter, L.M.6
  • 11
    • 0029883729 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
    • Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC: Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996, 14:1224-1235. Higher maximally tolerated doses of topotecan were achieved when initiation of G-CSF therapy was delayed for 24 hours following chemotherapy compared with concurrent administration.
    • (1996) J Clin Oncol , vol.14 , pp. 1224-1235
    • Rowinsky, E.K.1    Grochow, L.B.2    Sartorius, S.E.3    Bowling, M.K.4    Kaufmann, S.H.5    Peereboom, D.6    Donehower, R.C.7
  • 12
    • 0028217482 scopus 로고
    • Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma
    • Grem JL, McAtee N, Murphy RF, Hamilton JM, Balls F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A, et al.: Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994, 12:560-568.
    • (1994) J Clin Oncol , vol.12 , pp. 560-568
    • Grem, J.L.1    McAtee, N.2    Murphy, R.F.3    Hamilton, J.M.4    Balls, F.5    Steinberg, S.6    Arbuck, S.G.7    Setser, A.8    Jordan, E.9    Chen, A.10
  • 13
    • 0027332976 scopus 로고
    • A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies
    • Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG, et al.: A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res 1993, 53:5929-5933.
    • (1993) Cancer Res , vol.53 , pp. 5929-5933
    • Shaffer, D.W.1    Smith, L.S.2    Burris, H.A.3    Clark, G.M.4    Eckardt, J.R.5    Fields, S.M.6    Weiss, G.R.7    Rinaldi, D.A.8    Bowen, K.J.9    Kuhn, J.G.10
  • 15
    • 0028256428 scopus 로고
    • A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
    • Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, et al.: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994, 83:2086-2092.
    • (1994) Blood , vol.83 , pp. 2086-2092
    • Ohno, R.1    Naoe, T.2    Kanamaru, A.3    Yoshida, M.4    Hiraoka, A.5    Kobayashi, T.6    Ueda, T.7    Minami, S.8    Morishima, Y.9    Saito, Y.10
  • 16
    • 8944234342 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group
    • Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, et al.: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996, 14:2150-2159. Administration of GM-CSF during induction therapy provides no therapeutic benefit in the treatment of acute myelogenous leukemia. Use of this cytokine after chemotherapy was associated with a reduction in the complete remission rate and adverse effects such as fluid retention.
    • (1996) J Clin Oncol , vol.14 , pp. 2150-2159
    • Zittoun, R.1    Suciu, S.2    Mandelli, F.3    De Witte, T.4    Thaler, J.5    Stryckmans, P.6    Hayat, M.7    Peetermans, M.8    Cadiou, M.9    Solbu, G.10
  • 17
    • 0029978349 scopus 로고    scopus 로고
    • Use of cytokines in the treatment of acute myelocytic leukemia: A critical review
    • Geller RB: Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996, 14:1371-1382. A review of six phase III trials that used a CSF during AML induction found this combination to be safe with an improvement in neutrophil recovery.
    • (1996) J Clin Oncol , vol.14 , pp. 1371-1382
    • Geller, R.B.1
  • 18
    • 0029067674 scopus 로고
    • Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial
    • Ottman OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, et al.: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995, 86:444-450. Administration of G-CSF during ALL induction therapy was found to be safe and led to a shorter duration of neutropenia and earlier completion of chemotherapy.
    • (1995) Blood , vol.86 , pp. 444-450
    • Ottman, O.G.1    Hoelzer, D.2    Gracien, E.3    Ganser, A.4    Kelly, K.5    Reutzel, R.6    Lipp, T.7    Busch, F.W.8    Schwonzen, M.9    Heil, G.10
  • 19
    • 0029872332 scopus 로고    scopus 로고
    • Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation
    • Kanda Y, Akiyama H, Tanikawa S, Sakamaki H, Sasaki T, Takamoto S, Yasusuke O: Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. Am J Hematol 1996, 51:265-268. Two pateints who were treated with high-dose cyclophosphamide, etoposide, and busulfan were concurrently given G-CSF and both experienced hepatic veno-occlusive disease.
    • (1996) Am J Hematol , vol.51 , pp. 265-268
    • Kanda, Y.1    Akiyama, H.2    Tanikawa, S.3    Sakamaki, H.4    Sasaki, T.5    Takamoto, S.6    Yasusuke, O.7
  • 20
    • 9044220233 scopus 로고    scopus 로고
    • Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine
    • Weintraub M, Adde MA, Venzon DJ, Shad AT, Horak ID, Neely JE, Seibel NL, Gootenberg J, Arndt C, Nieder ML, Magrath IT: Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996, 14:935-940. Despite the fact that overlap of CSF administration with vincristine occurred in only one of the three doses in each cycle, severe atypical neuropathy was evident in 39% of patients compared with approximately 4% of control subjects.
    • (1996) J Clin Oncol , vol.14 , pp. 935-940
    • Weintraub, M.1    Adde, M.A.2    Venzon, D.J.3    Shad, A.T.4    Horak, I.D.5    Neely, J.E.6    Seibel, N.L.7    Gootenberg, J.8    Arndt, C.9    Nieder, M.L.10    Magrath, I.T.11
  • 21
    • 0029975952 scopus 로고    scopus 로고
    • Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor for intermediate-grade non-Hodgkin's lymphoma
    • Niitsu N, Umeda M: Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor for intermediate-grade non-Hodgkin's lymphoma. Eur J Haematol 1996, 56:163-167. A minimal overlap of G-CSF with the COP-BLAM regimen allowed for a shortened interval between chemotherapy cycles without accentuating toxicity.
    • (1996) Eur J Haematol , vol.56 , pp. 163-167
    • Niitsu, N.1    Umeda, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.